Boardroom Alpha
Boardroom Alpha
LABT · Additional Proxy Materials (DEFA14A) · Filed August 10, 2026

Lakewood-amedex Biotherapeutics Inc — Additional Proxy Materials (DEFA14A)

Form
DEFA14A
Filed
August 10, 2026
Ticker
LABT
Accession
0001213900-26-087338
Boardroom Alpha · Filing insights

Lakewood-Amedex board urges voting FOR all five proposals at the Sept. 22, 2026 meeting.

About Lakewood-amedex Biotherapeutics Inc
Market cap
$5M
Board grade
D
Sector
Healthcare
 

 

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

 

Schedule 14A

 

Proxy Statement Pursuant to Section 14(a) of the
Securities Exchange Act of 1934

 

Filed by the Registrant
   
Filed by a Party other than the Registrant

 

Check the appropriate box:

 

Preliminary Proxy Statement
   
Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))
   
Definitive Proxy Statement
   
Definitive Additional Materials
   
Soliciting Material under § 240.14a-12

 

LAKEWOOD-AMEDEX BIOTHERAPEUTICS INC.

(Name of Registrant as Specified In Its Charter)

 

 

(Name of Person(s) Filing Proxy Statement, if other than the Registrant)

 

Payment of Filing Fee (Check all boxes that apply):

 

No fee required
   
Fee paid previously with preliminary materials.
   
Fee computed on table in exhibit required by Item 25(b) per Exchange Act Rules 14a-6(i)(1) and 0-11

 

 

 

  

 

IMPORTANT NOTICE REGARDING THE AVAILABILITY OF PROXY MATERIALS FOR THE FOR THE SHAREHOLDER MEETING BEING HELD ON SEPTEMBER 22 , 2026 Lakewood - Amedex Biotherapeutics Inc. c/o ClearTrust, LLC - Transfer Agent 2420 Brunello Trace Lutz, Florida 33558 * SPECIMEN * 1 MAIN STREET ANYWHERE PA 99999 - 9999 DATE: TIME: September 22, 2026 10:00 a.m. Eastern Time LOCATION: www.cleartrustonline.com/LABT CONTROL NUMBER: VOTING CLOSES SEPTEMBER 21, 2026 AT 11:59 PM HOW TO REQUEST PAPER COPIES OF OUR MATERIALS EMAIL: inbox@cleartrusttransfer.com PHONE: 1 - 813 - 235 - 4490 MAIL: ClearTrust, LLC 2420 Brunello Trace Lutz, FL 33558 THIS COMMUNICATION REPRESENTS A NOTICE TO ACCESS A MORE COMPLETE SET OF PROXY MATERIALS AVAILABLE TO YOU ON THE INTERNET . WE ENCOURAGE YOU TO ACCESS AND REVIEW ALL OF THE IMPORTANT INFORMATION CONTAINED IN THE PROXY MATERIALS BEFORE VOTING . THE FOLLOWING PROXY MATERIALS ARE BEING MADE AVAILABLE AT : www . cleartrustonline . com/labt • NOTICE OF ANNUAL MEETING AND PROXY STATEMENT IF YOU WANT TO RECEIVE A PAPER OR EMAIL COPY OF THE PROXY MATERIALS, INCLUDING THE NOTICE, PROXY STATEMENT, AND FORM OF PROXY, YOU MUST REQUEST ONE . YOU WILL NOT OTHERWISE RECEIVE A PAPER OR EMAIL COPY . THERE IS NO CHARGE TO YOU FOR REQUESTING A COPY . TO FACILITATE TIMELY DELIVERY, PLEASE MAKE THE REQUEST, AS INSTRUCTED ABOVE, BEFORE SEPTEMBER 8 , 2026 . YOU MAY VOTE AT WWW . CLEARTRUSTONLINE . COM/LABT , BY PHONE AT 1 - 813 - 235 - 4490 , OR AS INDICATED ON ANY PROXY CARD THAT YOU RECEIVE . THE PURPOSES OF THIS MEETING ARE AS FOLLOWS : 1. ELECTION OF DIRECTORS (Proposal 1): Kelvin Cooper, Ph.D. Leonard J. DeRoma Doug Manion, M.D., FRCP Joseph Tucker, Ph.D. 2. AMENDMENT TO ARTICLES OF INCORPORATION TO INCREASE AUTHORIZED SHARES OF COMMON STOCK FROM 12 , 500 , 000 TO 100 , 000 , 000 (Proposal 2 ) . 3. AUTHORIZE THE BOARD, IN ITS SOLE AND ABSOLUTE DISCRETION, AND WITHOUT FURTHER ACTION OF THE STOCKHOLDERS, TO FILE A CERTIFICATE OF AMENDMENT TO THE COMPANY’S ARTICLES OF INCORPORATION, TO EFFECT ONE OR MORE REVERSE STOCK SPLITS OF THE COMPANY’S ISSUED AND OUTSTANDING COMMON STOCK AT A RATIO TO BE DETERMINED BY THE BOARD, BUT NOT TO EXCEED A CUMULATIVE RATIO OF ONE - FOR - TWENTY ( 1 : 20 ) (Proposal 3 ) . 4. APPROVAL OF AMENDMENT TO THE LAKEWOOD - AMEDEX INC . 2020 EQUITY INCENTIVE PLAN TO INCREASE THE NUMBER OF SHARES AVAILABLE FOR ISSUANCE TO 400 , 000 (Proposal 4 ) . 5. RATIFICATION OF APPOINTMENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM (Proposal 5 ) . After careful consideration, the Board of Directors of Lakewood - Amedex Biotherapeutics Inc . recommends that you vote “FOR” all proposals . MORE INFORMATION ABOUT ATTENDING THE MEETING AND VOTING IS CONTAINED IN THE PROXY STATEMENT . PLEASE NOTE - THIS IS NOT A PROXY CARD - YOU CANNOT VOTE BY RETURNING THIS CARD . INSTRUCTIONS TO ACCESS THE VIRTUAL MEETING CAN BE FOUND ON THE REVERSE SIDE OF THIS NOTICE .

  

VIRTUAL MEETING INSTRUCTIONS 1. On the day of the meeting, visit cleartrustonline.com/labt 2. Click “Vote + Join Meeting” 3. Enter your 12 - digit Control Number, located on the reverse side of this page. 4. Click “Join Meeting” 5. You will be routed into Zoom and prompted to enter your shareholder account name and email. 6. Click to "Join the Webinar in Progress". You will be prompted to launch Zoom on your computer. Follow prompts to "Launch" or "Allow" Zoom. If you do not wish to launch the Zoom app, you can opt to join the meeting in your web browser by clicking "Join from your browser". 7. Zoom will ask if you would like to use audio from your computer or from your phone. Click on your selection and Zoom will connect you to the meeting. SUPPORT The Shareholder Meeting Help Line will open one hour before the meeting is scheduled to begin and will remain open for the duration of the meeting. Should you need any technical assistance, please feel free to dial into the help line. Call 813 - 308 - 9980 | Access Code 675813 TIPS • It is easiest to access the meeting from a computer or laptop . If you choose to access the meeting from your tablet or smart phone, you may be prompted to download the Zoom app . If you use a computer or laptop, no download is needed . You can simply click “Join from your browser” at the bottom of the screen when prompted . • If you would like to join by phone (audio only) to listen to the meeting (without using a computer), please contact ClearTrust by September 21 , 2026 at 5 P . M . to register your phone number and obtain phone instructions : 813 - 235 - 4490 . • Registered and Beneficial Holders must vote by September 21 , 2026 at 11 : 59 PM . • If you hold shares in a brokerage account, you must pre - register for the meeting by no later than September 21 , 2026 at 5 P . M . by following the instructions located at www . cleartrustonline . com/labt .

  

From this filing to the vote

Forecast every director vote the day the proxy files.

Meeting Forecast scores each director up for re-election + every contested situation, rebuilt daily across 6,000+ U.S. public companies. The same model that called the LULU contested proxy lives on every meeting you see here.

Independent — issuer-pays-free, ideology-free, U.S.-owned.

More filings

Other filings from Lakewood-amedex Biotherapeutics Inc (LABT)

Reference

Frequently asked questions

When did Lakewood-amedex Biotherapeutics Inc file this DEFA14A?
Lakewood-amedex Biotherapeutics Inc (LABT) filed this Additional Proxy Materials (DEFA14A) with the SEC on August 10, 2026. The accession number assigned by EDGAR is 0001213900-26-087338.
What does a DEFA14A disclose?
DEFA14A is additional definitive proxy soliciting material filed in connection with a shareholder meeting — supplemental letters, slides, or amendments issued after the main proxy statement.
What is the key takeaway from this filing?
Lakewood-Amedex board urges voting FOR all five proposals at the Sept. 22, 2026 meeting. This is Boardroom Alpha's one-line summary of the additional proxy materials; see the full filing text above for the formal disclosure.
Where can I find Lakewood-amedex Biotherapeutics Inc's prior proxy statements on EDGAR?
The SEC EDGAR browser lists every DEFA14A Lakewood-amedex Biotherapeutics Inc has filed under CIK 2079272, sortable by date. Use the "View on SEC EDGAR" link in the page header, or browse directly via https://www.sec.gov/cgi-bin/browse-edgar.
Disclaimer

The opinions and information contained herein have been obtained or derived from sources believed to be reliable, but Boardroom Alpha cannot guarantee its accuracy and completeness, and that of the opinions based thereon.

This report contains opinions and is provided for informational purposes only – it does not constitute investment, legal or tax advice. You should not rely solely upon the research herein for purposes of transacting securities or other investments, and you are encouraged to conduct your own research and due diligence, and to seek the advice of a qualified securities professional before you make any investment.

None of the information contained in this report constitutes, or is intended to constitute a recommendation by Boardroom Alpha of any particular security or trading strategy or a determination by Boardroom Alpha that any security or trading strategy is suitable for any specific person. To the extent any of the information contained herein may be deemed to be investment advice, such information is impersonal and not tailored to the investment needs of any specific person.

No representation or warranty, expressed or implied, is made on behalf of Boardroom Alpha as to the accuracy or completeness of the information contained herein. Boardroom Alpha does not accept any liability for any direct, indirect or consequential loss or damage suffered by any person as a result of relying on all or any part of this research and any liability is expressly disclaimed.

Full disclaimer